Categories Earnings, Technology

Earnings Summary: Catalent (CTLT) slips to a loss in Q2; revenue down 10%

Catalent, Inc. (NYSE: CTLT), a provider of delivery technologies and development solutions to the pharmaceutical industry, on Friday reported a net loss for the second quarter of 2024, reflecting a decline in revenues.

  • Net revenue came in at $1.03 billion in the December quarter, which is down 10% from the prior year quarter
  • The company reported a net loss of $204 million or $1.12 per share for the second quarter, compared to earnings of $81 million or $0.44 per share in Q2 2023
  • On an adjusted basis, loss per share was $0.24 in Q2, vs. a profit of $0.67 per share a year earlier
  • Q2 adjusted EBITDA fell 56% from last year to $124 million as reported, and dropped 57% in constant currency
  • During the quarter, Catalent raised $600 million in term loans and used the proceeds to pay down debt
  • Recently, the company agreed to be acquired by Novo Holdings an all-cash deal that values it at $16.5 billion

Listen to the conference calls as they happen. Don't miss a beat! With AlphaStreet Intelligence, you can listen to live calls and interviews as they happen, so you never have to worry about missing out on important information.

Most Popular

CCL Earnings: Carnival Corp. Q4 2024 revenue rises 10%

Carnival Corporation & plc. (NYSE: CCL) Friday reported strong revenue growth for the fourth quarter of 2024. The cruise line operator reported a profit for Q4, compared to a loss

Key metrics from Nike’s (NKE) Q2 2025 earnings results

NIKE, Inc. (NYSE: NKE) reported total revenues of $12.4 billion for the second quarter of 2025, down 8% on a reported basis and down 9% on a currency-neutral basis. Net

FDX Earnings: FedEx Q2 2025 adjusted profit increases; revenue dips

Cargo giant FedEx Corporation (NYSE: FDX), which completed an organizational restructuring recently, announced financial results for the second quarter of 2025. Second-quarter earnings, excluding one-off items, were $4.05 per share,

Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top